These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31415451)

  • 1. BASELINE CHARACTERISTICS OF VITREOMACULAR TRACTION PROGRESSING TO FULL-THICKNESS MACULAR OR LAMELLAR HOLES IN THE PHASE III TRIALS OF ENZYMATIC VITREOLYSIS.
    Schneider EW; Jaffe GJ
    Retina; 2020 Aug; 40(8):1579-1584. PubMed ID: 31415451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
    Jackson TL; Regillo CD; Girach A; Dugel PU;
    Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
    Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
    Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Anatomic and Visual Function Outcomes in Patients With Full-Thickness Macular Hole in Ocriplasmin Phase 3 Trials.
    Dugel PU; Regillo C; Eliott D
    Am J Ophthalmol; 2015 Jul; 160(1):94-9.e1. PubMed ID: 25818925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
    Abou Ltaif S; Herbert L
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
    Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
    Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral vitreomacular traction resolved with a single intravitreal ocriplasmin injection.
    Katz RS
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(3):239-42. PubMed ID: 24708167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
    Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK
    Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
    N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
    Lenk J; Matthé E; Ventzke S; Pillunat LE; Sandner D
    Klin Monbl Augenheilkd; 2018 Jan; 235(1):73-80. PubMed ID: 28282697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.
    Haller JA; Stalmans P; Benz MS; Gandorfer A; Pakola SJ; Girach A; Kampik A; Jaffe GJ; Toth CA;
    Ophthalmology; 2015 Jan; 122(1):117-22. PubMed ID: 25240630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different modes of full-thickness macular hole formation.
    Bringmann A; Unterlauft JD; Barth T; Wiedemann R; Rehak M; Wiedemann P
    Exp Eye Res; 2021 Jan; 202():108393. PubMed ID: 33301774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter-Reichart S; Mennel S
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
    Modi YS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
    Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
    Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
    Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C
    Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.